TEVA PHARMACEUTICAL INDUSTRIES LTD
Close on Oct 19, 2026
- Market cap
- $48.13B
- P/E (TTM)
- 68.9
- Dividend yield
- –
About Teva Pharmaceutical Industries
Pharmaceutical Preparations, SIC 2834
Teva Pharmaceutical Industries is a global biopharmaceutical enterprise that develops, manufactures, and commercializes generic pharmaceuticals, biosimilars, innovative therapies, and over-the-counter healthcare products. Its commercial operations are organized into three primary geographic segments: the United States, Europe, and International Markets, supplemented by auxiliary operations in active pharmaceutical ingredient manufacturing, contract production, and product out-licensing. The company targets core therapeutic areas including central nervous system conditions, respiratory illnesses, and oncology. Teva provides medicines to diverse healthcare and commercial clients, including wholesale distributors, retail drug chains, independent pharmacies, mail-order distributors, hospitals, and physician practices.
The company maintains an extensive international footprint, operating with approximately 34,000 employees across 57 markets worldwide. Its commercial network spans substantial infrastructure throughout the United States, European markets, and over 35 countries within its International Markets division. Teva maintains its corporate headquarters in Israel.
Summary of the business section of Teva Pharmaceutical Industries's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Founded
- 1901
- Headquarters
- Tel Aviv, Israel
- Address
- Teva Pharmaceutical Industries Limited, 124 Dvora Hanevi'A St.
- Phone
- 972 (3) 914-8213
- Website
- www.teva.co.il
- Employees
- 33,950, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman, Israel
Stock & identifiers
- Ticker
- TEVA
- Exchange
- NYSE
- Shares outstanding
- 1.17B, Jun 30, 2026
- Public float
- $18.16B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jul 1, 2004; 2-for-1, Dec 6, 2002; 2-for-1, Feb 23, 2000; 2-for-1, Apr 14, 1993
- SEC CIK
- 818686
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian Savage | Interim Chief Legal Officer | 15,842 |
| Amir Weiss | Chief Accounting Officer | 13,071 |
| Evan Lippman | EVP, Business Development | 25,591 |
| Placid Jover | "See ""Remarks""" | 19,601 |
| Eric A. Hughes | "See ""Remarks""" | 134,877 |
| Matthew Shields | EVP, Global Operations | 0 |
| Eliyahu Sharon Kalif | EVP, Chief Financial Officer | 65,621 |
| Richard D. Francis | President and CEO | 1,183,682 |
| Richard Daniell | EVP, Europe Commercial | 55,755 |
| Christine Fox | EVP, U.S. Commercial | 63,647 |
| Mark Sabag | "See ""Remarks""" | 80,760 |
| David R. McAvoy | EVP, Chief Legal Officer | 13,027 |
| Roberto Mignone | Director | 119,807 |
| Ronit Satchi-Fainaro | Director | 111,986 |
| Tal Zvi Zaks | Director | 73,247 |
| Rosemary A. Crane | Director | 127,739 |
| Sol J. Barer | Director | 448,011 |
| Gerald M. Lieberman | Director | 130,149 |
| Perry Nisen | Director | 119,807 |
| Chen Lichtenstein | Director | 19,296 |
| Amir Elstein | Director | 2,118,455 |
| Varda Shalev | Director | 22,504 |
| Janet S. Vergis | Director | 73,697 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Richard Francis | $19.17M | $54.98M | $6.59M | $323 | $156 |
| FY2024 Richard Francis | $15.52M | $40.92M | $5.65M | $228 | $118 |
| FY2023 Richard Francis | $25.71M | $26.19M | $4.52M | $108 | $109 |
| FY2022 Kare Schultz | $15.53M | $17.21M | $3.98M | $95 | $108 |
| FY2022 Richard Francis | $15.53M | $17.21M | $3.98M | $95 | $108 |
| FY2021 Kare Schultz | $14.68M | $7.57M | $3.74M | $83 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Teva’s global workforce consisted of 33,950 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 14, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Aug 5, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 2, 2018 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 7, 2015 | Tender offer | Third-party tender offer for the company's shares |
| Jan 23, 2014 | Tender offer | Third-party tender offer for the company's shares |
| May 23, 2012 | Delisting | Notice of delisting from exchange (Form 25) |
| May 23, 2012 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 16, 2008 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Sep 2, 2005 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Nov 26, 2003 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jan 16, 2001 | Name change | Name changed from TEVA PHARMACEUTICAL INDUSTRIES LIMITED to TEVA PHARMACEUTICAL INDUSTRIES LTD |